A novel prostaglandin I
2 (PGI
2) analogue, beraprost sodium, is the first launched drug as an orally active PGI
2. PGI
2 was discovered in 1976, and has attracted much attention as a medicine for cardiovascular diseases such as strokes and heart attacks because of its potent antiplatelet and vasodilating effect. However, PGI
2 is extremely unstable for the use as practical medicines. Thus, stable PGI
2 analogues have been explored by a large number of researchers in the world. Just after the discovery of PGI
2, we started a research on chemically and metabolically stable PGI
2 derivatives with longer duration of action and less adverse reaction. We invented a novel class of stable PGI
2, 5, 6, 7-trinor-4, 8-infer-m-phenylenePGI
2 analogues that have the phenol moiety instead of the enolether moiety of PGI
2. Further efforts were devoted to enhance the efficacy of the PGI
2. analogues and to eliminate their side effects, and an orally active analogue, beraprost sodium, was obtained. In order to establish the synthetic route of beraprost sodium, various novel processes were invented, including ortho-selective metalation of bromoanisoles by means of Grignard reagents, copper-catalyzed S
N2' cyclization to prepare cyclopenta [b] benzofuran, and stereo-selective elongation of the omega-side chain by Prins reaction. Beraprost sodium inhibited platelet aggregation induced by adenosine 5'-diphosphate (ADP), collagen and arachidonic acid. It was shown that the drug
抄録全体を表示